Sarepta Therapeutics’ (SRPT) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $163.00 price target on the biotechnology company’s stock.

A number of other analysts have also issued reports on SRPT. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price for the company. HC Wainwright reissued a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Finally, StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.23.

Sarepta Therapeutics Stock Down 27.4 %

SRPT stock opened at $73.54 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market capitalization of $7.14 billion, a P/E ratio of 58.83 and a beta of 0.79. Sarepta Therapeutics has a 52-week low of $73.06 and a 52-week high of $173.25. The company’s 50 day simple moving average is $110.18 and its 200-day simple moving average is $119.13.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Sarepta Therapeutics by 21.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 300 shares during the period. Oppenheimer Asset Management Inc. increased its position in Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after buying an additional 145 shares during the period. Huntington National Bank lifted its holdings in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Sarepta Therapeutics by 3.3% during the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after buying an additional 86 shares during the last quarter. Finally, Commerce Bank boosted its position in shares of Sarepta Therapeutics by 15.7% in the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 274 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.